DanielHalperinMD

PubMed

• Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study.
  Qing H Meng, Thorvardur R Halfdanarson, Joshua A Bornhorst, Henning Jann, Shagufta Shaheen
  Clinical Cancer Research. 2024-12-16
• Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms.
  Alejandra G Serrano, Pedro Rocha, Cibelle Freitas Lima, Allison Stewart, Bingnan Zhang
  NPJ Precision Oncology. 2024-11-19
• 1 citations
  Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.
  Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Mohammad M Fanaeian, Mark Knafl
  JAMA Oncology. 2024-11-01

Abstracts/Posters

• A prospective, multi-institutional phase II study pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumors.
  Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH, NANETS: North American Neuroendocrine Tumor Society Annual Meeting, Nashville, TN, USA, 10/6/2014
• Clinical Presentation and Outcomes in Patients with Advanced Pheochromcytoma/Paraganglioma: Evidence of Temozolomide Efficacy
  Halperin DM, Brais L, Ramaiya NH, Kulke MH, ASCO Annual Meeting, Chicago, IL, USA, 6/2014
• A phase I study of the anti-IGF-1R monoclonal antibody, IMC-A12, and everolimus in well-differentiated neuroendocrine tumors
  Dasari A, Phan AT, Gupta S, Hess KR, Culotta KS, Rashid A, Yeung SJ, Chen HX, Dong M, Halperin DM, Subbiah IM, Meric-Bernstam F, Yao JC, ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 1/1/2014
• Assessing pretest probability in phase II trials: One step back before two steps forward
  Halperin DM, Dagohoy C, Lee JJ, Yao JC, ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 1/2014
• A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.
  Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff P, NANETS: North American Neuroendocrine Tumor Society Annual Meeting, Charleston, SC, USA, 10/2013
• Predictive value of phase II clinical trials in pancreatic cancer: Rethinking the road to progress.
  Halperin DM, Lee JJ, Yao JC, ASCO Annual Meeting, Chicago, IL, USA, 6/2013
• Join now to see all

Lectures

• A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs). 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020